The publication of trial data in a reputable medical journal often validates the efficacy and safety of a pharmaceutical product, which can lead to increased adoption by healthcare providers and a positive impact on the company's revenue. For BioCryst, this could translate into higher sales of Orladeyo and improved investor sentiment in the short term, as the market responds to the validation of the drug's clinical benefits.